The Significance of GW501516 (CAS 317318-70-0) and Its Manufacturers
GW501516, also known by its chemical name GSK-516 or Cardarine, is a compound developed for its potential therapeutic uses, particularly in metabolic and cardiovascular diseases. Its CAS number, 317318-70-0, is often used in the pharmaceutical and research sectors to uniquely identify this substance. Over the years, GW501516 has gained attention not only in medical research but also among athletes and bodybuilders seeking to enhance their physical performance. Understanding the significance of GW501516 and its manufacturers sheds light on its role in science and sport.
The Significance of GW501516 (CAS 317318-70-0) and Its Manufacturers
Despite its promising beginnings, GW501516's journey turned controversial after the discovery of significant safety concerns. In preclinical studies, it was found that prolonged use of this compound could lead to cancer in animal models. This alarming finding led to the halting of clinical trials and its withdrawal from further development by GlaxoSmithKline in the mid-2000s. Nonetheless, its performance-enhancing properties captured the interest of the sports community, leading to its illicit use among athletes seeking an edge in competition.
As a result, several manufacturers began producing GW501516 legally for research purposes. These entities operate within a complex regulatory framework, often providing the compound to laboratories and researchers investigating its properties, albeit under strict guidelines. Purchasers typically include researchers conducting preclinical studies on metabolic diseases, as well as those exploring its potential therapeutic effects in human conditions. Reliable manufacturers adhere to quality assurance protocols to ensure the purity and efficacy of their GW501516 products. Their compliance with good manufacturing practices (GMP) has become essential in a market that can be rife with counterfeit substances.
Yet, the clandestine use of GW501516 in athletics poses challenges for sports organizations and regulatory bodies. The World Anti-Doping Agency (WADA) included GW501516 in its list of prohibited substances, specifically due to its performance-enhancing capabilities. Athletes caught using GW501516 face serious repercussions, including suspensions and damage to their reputations.
In conclusion, GW501516 (CAS 317318-70-0) serves as a prime example of the intersection between therapeutic development and sports enhancement. While its initial promise in medical research was eclipsed by safety concerns, its allure remains strong within certain circles. Manufacturers involved in its production must navigate a landscape fraught with scientific inquiry and ethical considerations, remaining vigilant in the efforts to support research while discouraging abuse in the competitive sports arena. As research continues, the future of GW501516 may still hold unforeseen opportunities, but its journey remains one defined by caution and scrutiny.